CONNECT WITH US
Funding Tracker

Funding Tracker

HealthKart crosses Rs 2,000 Cr revenue in FY26, PBT rises 30%

Entrackr logo

Published on

Add as a preferred source on Google
HealthKart crosses Rs 2,000 Cr revenue in FY26, PBT rises 30%

As HealthKart reportedly gears up for its IPO, the health supplement brand appears to be building the financial profile investors look for in a public market candidate: strong revenue growth, scale and sustained profitability. The company crossed the Rs 2,000 crore revenue mark in FY26, while its profit before tax increased 30% during the year.

HealthKart’s revenue from operations rose 56.2% to Rs 2,052 crore in FY26 from Rs 1,313 crore in FY25, according to its consolidated annual statements sourced from the Registrar of Companies (RoC).

The company owns and operates a portfolio of nutrition and wellness brands, including MuscleBlaze, The Protein Zone, TrueBasics, HK Vitals, bGreen, Nouriza and Gritzo.

Sales of products remained the main revenue driver, accounting for nearly 99% of operating revenue. Product sales increased 59.2% to Rs 2,033 crore in FY26 from Rs 1,279 crore in the previous fiscal year. The company also earns revenue from services and other activities. Including other income of Rs 54 crore, its total income rose to Rs 2,106 crore in FY26 from Rs 1,368 crore in FY25.

The growth, however, came alongside a rise in expenses. Procurement remained HealthKart’s largest cost, increasing 71.9% to Rs 1,071 crore in FY26 from Rs 623 crore in FY25. The company also stepped up its spending on advertising and marketing, which rose 53.2% to Rs 403 crore during the year.

Employee benefits, commissions, freight and other overheads pushed total expenses up 55.7% to Rs 1,982 crore in FY26 from Rs 1,273 crore in FY25.



Source link
Related Topics:Funding Tracker

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.